ACTUACIÓN FRENTE A COVID19 EN RECEPTORES DE TRASPLANTE DE PROGENITORES HEMATOPOYÉTICOS Y PACIENTES ONCOHEMATOLÓGICOS (COVID-19) (GETH-COV-2020-01)

First published: 30/03/2020

Last updated: 31/08/2020

Study Finalised

Administrative details

EU PAS number

EUPAS34365

Study ID

36967

DARWIN EU® study

No

Study countries

Spain

Study description

Retrospective study in which TPH/ONCOHEMATOLOGICAL patients will be included, that is to say, immunosuppressed patients such as the recipients of allogeneic or autologous transplants of haematopoietic progenitors (alo or auto-TPH), of CAR-T therapy and oncohaematological patients in chemotherapeutic and/or immunosuppressive treatment from centres participating in the GETH. The collection will be done by CRD on-line or on paper.It will be done in two phases:1st phase at the time of diagnosis, only the minimum data that will allow later identification of the patient will be collected (initial registration sheet). Send by email.2nd phase once the episode is over (Complementary registration sheet). Send by email.Translated with www.DeepL.com/Translator (free version)

Study status

Finalised

Research institutions and networks

Institutions

Multiple centres: 70 centres are involved in the study

Contact details

Study institution contact

JOSE LUIS PIÑANA jlpinana@gmail.com

Study contact

jlpinana@gmail.com

Primary lead investigator

JOSE LUIS PIÑANA

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 20/03/2020

Actual: 20/03/2020

Study start date

Planned: 23/03/2020

Actual: 23/03/2020

Data analysis start date

Planned: 30/06/2020

Actual: 15/06/2020

Date of final study report

Planned: 30/07/2020

Actual: 16/07/2020

Sources of funding

- Other

More details on funding

GETH

Study protocol

RT-GETH-COVID-V2.pdf (1.23 MB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Other

Study topic, other:

Diagnostic procedure

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Data collection methods:

Primary data collection

Main study objective:

INCIDENT

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medical condition to be studied

Diagnostic procedure

Additional medical condition(s)

HEMATOLOGIC PATIENT WITH CODIV-19 INFECTION

Population studied

Short description of the study population

TPH/ONCOHEMATOLOGICAL patients will be included, that is to say, immunosuppressed patients such as the recipients of allogeneic or autologous transplants of haematopoietic progenitors (alo or auto-TPH), of CAR-T therapy and oncohaematological patients in chemotherapeutic and/or immunosuppressive treatment from centres participating in the GETH.

Age groups

- **Paediatric Population (< 18 years)**
- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Special population of interest

Immunocompromised

Estimated number of subjects

500

Study design details

Outcomes

use of treatments or interactions resulting from this

Data analysis plan

Análisis estadístico: JULIO 2020

Documents

Study results

Piñana_et_al-2020-Experimental_Hematology_&_Oncology (1).pdf (1.46 MB)

Study publications

Yang J, Zheng YA, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Pre…

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L…

Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y. Cl…

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du…

Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, Clark JG. …

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Spontaneous reports of suspected adverse drug reactions

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No